H.C. Wainwright Reiterates Buy Rating on Niagen Bioscience (NAGE)

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $11.00 price target on Niagen Bioscience (NASDAQ: NAGE).

The analyst commented: "A significant legal milestone was recently reached in the long-running litigation between two privately held companies, namely W.R. Grace & Co. vs. Elysium. The U.S. District Court for the District of Delaware rejected Elysium's claims that the asserted patent was unenforceable. This ruling preserves the enforceability of the patent and represents another favorable outcome following the prior jury verdict finding infringement, further reinforcing the strength of the intellectual property surrounding crystalline nicotinamide riboside. As a reminder, W.R. Grace & Co. controls certain patents for NRC, and both Grace and Niagen have entered into litigation against Elysium in the past. We reiterate our Buy rating and 12-month price target of $11."

For an analyst ratings summary and ratings history on Niagen Bioscience click here. For more ratings news on Niagen Bioscience click here.

Shares of Niagen Bioscience closed at $3.19 yesterday.

You May Also Be Interested In

• Stifel Starts Arrowhead Pharma (ARWR) at Buy
• Microvision (MVIS) files $50M mixed shelf
• Entrée Resources names Chris Adams as new CEO effective July 17